# Almada Ventures Sells TailorMed for About $7.6 Million

*The publicly traded R&D partnership will record a gross cash profit of about $5 million in a deal reflecting a 3.15x multiple on its investment • Control of the company will pass to U.S. private equity firm GrowthCurve Capital*

- Published: 2026-11-02T17:49:06.608Z (Monday, November 2, 2026)
- Updated: 2026-11-12T20:07:22.864Z
- By: Shai Nogai
- Section: Capital Market
- Canonical: https://tv10.news/news/capital-market/126640/almada-ventures-sells-tailormed-for-about-7-6-million/
- Hebrew original (TV10): https://tv10.co.il/news/capital-market/126640/
- Publisher: TV10 Global (TV10, Israel’s economic channel). Translated from Hebrew with AI and an automated accuracy check.

Publicly traded R&D partnership Almada Ventures reported today (Monday) another full exit. Portfolio company TailorMed, which operates in digital health, completed a merger transaction under which New York-based private equity firm GrowthCurve Capital became its controlling shareholder.

![Manor Zemer, CEO of Almada Ventures. Courtesy photo.jpg](https://tv10.news/media/2026/11/43/43e58b42d2b75233eb9d50f6f5f2bdf032e102f29dffbe51076958b9b89638a4.jpg)

Manor Zemer, CEO of Almada | Photo: PR

As part of the move, Almada is selling its entire stake in the company for gross cash proceeds of about $7.6 million.

### A 3.15x multiple on the investment

Immediately before the transaction was completed, Almada held about 3.05% of TailorMed's share capital on a fully diluted basis. Against a cumulative investment cost of about $2.42 million, the current proceeds reflect a multiple of about 3.15x on the money and are expected to generate a gross profit of about $5 million for the partnership before taxes and expenses.

![Signing a deal. Photo: Shutterstock](https://tv10.news/media/2026/11/99/99928537e243033769666908a684317bd34dc4685688258519323292b52b7bec.jpg)

Signing a deal | Photo: Shutterstock

The value of the stake on the partnership's books stood at just about $3.97 million at the end of June 2026, meaning the proceeds achieved in the transaction are significantly higher than the book value.

### Record year for exits and cash distributions

The current transaction caps a series of successful exits for Almada during 2026.

Earlier this year, the partnership completed the sale of BioProtect to medical device giant Olympus in a $270 million transaction that generated a profit of about $8 million for Almada, alongside a profitable partial exit from Clanz Technologies.

![The U.S. dollar](https://tv10.news/media/2026/11/5d/5d59191211895c32cfcde55b30a6ec53f9c43734ed11c482bb9ada562ab0e9dd.jpg)

The U.S. dollar | Photo: Shutterstock

This series of exits enabled Almada to reach $12 million in approved distributions to investors over the course of the year, including capital reductions and dividends, placing the partnership in the top decile for cash returns relative to 2020-vintage funds, according to benchmark data from Carta.

### Accelerating artificial intelligence technologies in medicine

TailorMed develops technology solutions for health care providers, pharmacies and patients, aimed at easing the financial burden associated with medical treatments.

![Medicine and artificial intelligence, illustration](https://tv10.news/media/2026/11/fa/fa779e58821dedea8858912c24eaad1f86ab7c418e9c6e692e548647d2c0c7eb.png)

Medicine and artificial intelligence, illustration | Photo: raker, Shutterstock

GrowthCurve Capital's entry as controlling shareholder is intended to accelerate the expansion of TailorMed's operations and support the continued development of artificial intelligence-based solutions for the U.S. and global health care markets.
